New drug inclisiran aims to lower cholesterol better in chinese heart patients
NCT ID NCT06941792
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether inclisiran, a newer cholesterol-lowering drug, works better than standard treatments for Chinese patients with coronary heart disease. About 1,590 adults whose cholesterol is still high despite statins will receive either inclisiran or usual care. The main goal is to see how much LDL cholesterol drops after one year and how many patients reach their target levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
inclisiran
What this could lead to
If it works, this could offer a more effective way to control cholesterol and reduce heart disease risk in Chinese patients.
What could go wrong
This is a phase 4 trial, so inclisiran is already approved; the main question is how it performs in real-world Chinese patients. It may not show a big advantage over standard care, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY HEART DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigated Site
Taiyuan, Shanxi, 030000, China
-
Novartis Investigative Site
Anqing, Anhui, 246003, China
-
Novartis Investigative Site
Beijing, Beijing Municipality, 102218, China
-
Novartis Investigative Site
Chongqing, Chongqing Municipality, 400010, China
-
Novartis Investigative Site
Longyan, Fujian, 364099, China
-
Novartis Investigative Site
Jiamusi, Heilongjiang, 154002, China
-
Novartis Investigative Site
Zhengzhou, Henan, 451400, China
-
Novartis Investigative Site
Baotou, Inner Mongolia, 014010, China
-
Novartis Investigative Site
Shenyang, Liaoning, 110016, China
-
Novartis Investigative Site
Shenyang, Liaoning, 121100, China
-
Novartis Investigative Site
Jining, Shandong, 272000, China
-
Novartis Investigative Site
Weifang, Shandong, 261000, China
-
Novartis Investigative Site
Shanghai, Shanghai Municipality, 200065, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610031, China
-
Novartis Investigative Site
Ürümqi, Xinjiang Uygur Autonomous Region, 830054, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310007, China
-
Novartis Investigative Site
Jinhua, Zhejiang, 321000, China
-
Novartis Investigative Site
Ningbo, Zhejiang, 315000, China
-
Novartis Investigative Site
Wenzhou, Zhejiang, 325000, China